Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2,5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80-heptacosaoxadooctacontan-82-ol
2. Chebi:44817
3. 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
4. Q27120584
Molecular Weight | 1221.5 g/mol |
---|---|
Molecular Formula | C55H112O28 |
XLogP3 | -4.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 28 |
Rotatable Bond Count | 80 |
Exact Mass | 1220.73401291 g/mol |
Monoisotopic Mass | 1220.73401291 g/mol |
Topological Polar Surface Area | 269 Ų |
Heavy Atom Count | 83 |
Formal Charge | 0 |
Complexity | 1070 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21153
Submission : 2007-12-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22570
Submission : 2009-02-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27603
Submission : 2013-10-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28678
Submission : 2014-09-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29335
Submission : 2015-04-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29524
Submission : 2015-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35636
Submission : 2021-03-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35552
Submission : 2021-03-09
Status : Active
Type : IV
NDC Package Code : 57449-011
Start Marketing Date : 2023-05-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registration Number : 218MF20001
Registrant's Address : 2211 H. H. Dow Way, Midland MI 48674, United States
Initial Date of Registration : 2006-02-23
Latest Date of Registration : --
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ANALYTICAL
ABOUT THIS PAGE
A Lauromacrogol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lauromacrogol, including repackagers and relabelers. The FDA regulates Lauromacrogol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lauromacrogol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lauromacrogol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lauromacrogol supplier is an individual or a company that provides Lauromacrogol active pharmaceutical ingredient (API) or Lauromacrogol finished formulations upon request. The Lauromacrogol suppliers may include Lauromacrogol API manufacturers, exporters, distributors and traders.
click here to find a list of Lauromacrogol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lauromacrogol DMF (Drug Master File) is a document detailing the whole manufacturing process of Lauromacrogol active pharmaceutical ingredient (API) in detail. Different forms of Lauromacrogol DMFs exist exist since differing nations have different regulations, such as Lauromacrogol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lauromacrogol DMF submitted to regulatory agencies in the US is known as a USDMF. Lauromacrogol USDMF includes data on Lauromacrogol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lauromacrogol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lauromacrogol suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lauromacrogol Drug Master File in Japan (Lauromacrogol JDMF) empowers Lauromacrogol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lauromacrogol JDMF during the approval evaluation for pharmaceutical products. At the time of Lauromacrogol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lauromacrogol suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lauromacrogol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lauromacrogol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lauromacrogol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lauromacrogol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lauromacrogol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lauromacrogol suppliers with NDC on PharmaCompass.
Lauromacrogol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lauromacrogol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lauromacrogol GMP manufacturer or Lauromacrogol GMP API supplier for your needs.
A Lauromacrogol CoA (Certificate of Analysis) is a formal document that attests to Lauromacrogol's compliance with Lauromacrogol specifications and serves as a tool for batch-level quality control.
Lauromacrogol CoA mostly includes findings from lab analyses of a specific batch. For each Lauromacrogol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lauromacrogol may be tested according to a variety of international standards, such as European Pharmacopoeia (Lauromacrogol EP), Lauromacrogol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lauromacrogol USP).
LOOKING FOR A SUPPLIER?